High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5395-5399

  Santala, Simi ^a   Talvensaari Mattila, Anne ^a   Soini, Ylermi ^a,b   Honkavuori Toivola, Maria ^a   Santala, Markku ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CDKs; Cyclin A; Endometrial adenocarcinoma; Prognosis

Indexed keywords

CISPLATIN DERIVATIVE; CYCLIN A;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYCLIN A; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84904720637     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1703-9     Document Type: Article

References (18)

1. Finnish Cancer Registry. Cancer Statistics. 2011. http://www.cancer.fi/ syoparekisteri/en/statistics/. Accessed: 30 Apr 2013.
2. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105:109.
3. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. Int J Gynecol Obstet. 2006;95:S105-43.
4. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128:307-12. (Pubitemid 34569351)
5. Arafa M, Somja J, Dehan P, Kridelka F, Goffin F, Boniver J, et al. Current concepts in the pathology and epigenetics of endometrial carcinoma. Pathology. 2010;42:613-7.
6. Ellis PE, Ghaem-Maghami S. Molecular characteristics and risk factors in endometrial cancer: what are the treatment and preventative strategies? Int J Gynecol Cancer. 2010;20:1207-16.
7. Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma. Tumor Biol. 2012;33:935-41.
8. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumor Biol. 2013;34:571-6.
9. Stamatakos M, Palla V, Karaiskos I, Xiromeritis K, Alexiou I, Pateras I, et al. Cell cyclins: triggering elements of cancer or not? World J Surg Oncol. 2010;8:111.
10. Yam CH, Funga TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59:1317-26.
11. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2003;3:617-33. (Pubitemid 37101877)
12. Kayaselcuk F, Erkanli S, Bolat F, Seydaoglu G, Kuscu E, Demirhan B. Expression of cyclin H in normal and cancerous endometrium, its correlation with other cyclins, and association with clinicopathologic parameters. Int J Gynecol Cancer. 2006;16:402-8.
13. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol. 2008;61:36-42. (Pubitemid 351158223)
14. Gallorini M, Cataldi A, di Giacomo V. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs. 2012;26:377-91.
15. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol. 2011;226:341-9.
16. Kallakury BV, Ambros RA, Hayner-Buchan AM, Sheehan CE, Malfetano JH, Ross JS. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol. 1998;17:320-6. (Pubitemid 28447160)
17. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 2003;34:471-8. (Pubitemid 36666813)
18. Watanabe J, Nishimura Y, Tsunoda S, Kawaguchi M, Okayasu I, Kuramoto H. Liquid-based preparation for endometrial cytology - usefulness for predicting the prognosis of endometrial carcinoma preoperatively. Cancer. 2009;117:254-63.